scholarly journals Expression and clinical significance of programmed death ligand 1 in nasopharyngeal carcinoma

2018 ◽  
Author(s):  
Yuan Qu ◽  
Di Wang ◽  
Lin Yang ◽  
Hui‑Ying Liu ◽  
Wei Cui ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Clinical Significance ◽  
Programmed Death Ligand 1 ◽  
Programmed Death

scholarly journals Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Yabing Cao ◽  
Kin Iong Chan ◽  
Gungli Xiao ◽  
Yanqun Chen ◽  
Xibin Qiu ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Clinical Significance ◽  
Retrospective Review ◽  
Braf Mutation ◽  
Prognostic Value ◽  
Programmed Death Ligand 1 ◽  
Immunohistochemistry Analysis ◽  
Egfr Expression ◽  
Programmed Death ◽  
Poor Outcomes

Abstract Background The prognostic value of programmed death-ligand 1 (PD-L1) and BRAF expression in nasopharyngeal carcinoma (NPC) is not well-defined. In this study we investigated alterations in PD-L1, BRAF and EGFR by using immunohistochemistry analysis in a cohort of consecutively enrolled NPC patients. Methods A retrospective review of 154 NPC patients form our previous study (BMC Cancer. 2013; 13:226) were conducted. Survival and prognostic impacts were analyzed based on PD-L1, BRAF and EGFR expression levels. Results One hundred fifty four patients were included in this study. PD-L1 expression was detected in 87.7% of patients; 14.3% had 1–5% PD-L1 expression, 47.4% had 5–49% expression while 26% had ≥50% expression Higher PD-L1 expression was significantly associated with shorter PFS and OS. The median PFS was 25 months (95% CI 15.7–34.3 months) and OS was 35 months (95% CI 22.60–47.4 months) for patients with PD-L1 expression ≥50%; both median PFS and OS were not yet reached for patients with PD-L1 expression < 50%. PFS was significantly higher in BRAF mutation positive patients (5-year PFS: 55.1% vs. 30.8%, P = 0.044). Conclusion Tumor PD-L1 expression and BRAF mutation are associated with poor outcomes in patients with NPC. This study was retrospectively registered in ClinicalTrials.gov (NCT03989297) on 2019-6-18.

Clinical Significance of Programmed Death Ligand-1 Expression in Esophageal Squamous Cell Carcinoma

2020 ◽  
Vol 251 ◽  
pp. 321-328 ◽  
Author(s):  
Nozomi Ito ◽  
Hironori Tsujimoto ◽  
Hiroyuki Horiguchi ◽  
Hideyuki Shimazaki ◽  
Hiromi Miyazaki ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Significance ◽  
Squamous Cell ◽  
Programmed Death Ligand 1 ◽  
Programmed Death

The Prognostic Role of Programmed Death‐Ligand 1 in Nasopharyngeal Carcinoma

2020 ◽  
Vol 130 (11) ◽  
pp. 2598-2606 ◽  
Author(s):  
Michael Wotman ◽  
Saori W. Herman ◽  
Peter Costantino ◽  
Tristan Tham
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Prognostic Role ◽  
Programmed Death Ligand 1 ◽  
Programmed Death
Sign in / Sign up

Export Citation Format

Share Document